^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation + STK11 mutation + TP53 mutation

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    3845; 7157; 6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. (PubMed, Lung Cancer)
    Recent regulatory approvals of the KRAS-selective inhibitors sotorasib and adagrasib for patients with advanced or metastatic NSCLC harboring KRASG12C have transformed KRAS into a druggable target. Where available, next-generation sequencing is recommended to facilitate simultaneous testing of potentially actionable biomarkers in a single run to conserve tissue. Results from molecular testing should inform clinical decisions in treating patients with KRAS G12C-mutated advanced NSCLC.
    Review • Journal • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12 • KRAS mutation + STK11 mutation + TP53 mutation
    |
    Lumakras (sotorasib) • Krazati (adagrasib)
    over2years
    Concurrent STK11 and TP53 Mutations Correlate with a Unique Morphological Phenotype and Clinical Stage in Lung Adenocarcinomas (USCAP 2022)
    Despite the small sample size, the current cohort indicates that tumors harboring mutations involving STK11 and TP53 are associated with unfavorable morphology and high TNM stage. In addition, these tumors may benefit from treatment with immunotherapy.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • STK11 mutation • PD-L1 negative • ALK mutation • TP53 mutation + KRAS mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS mutation + TP53 mutation
    |
    PD-L1 IHC 22C3 pharmDx
    almost3years
    Concurrent STK11 and TP53 Mutations Correlate with a Unique Morphological Phenotype and Clinical Stage in Lung Adenocarcinomas (USCAP 2022)
    Despite the small sample size, the current cohort indicates that tumors harboring mutations involving STK11 and TP53 are associated with unfavorable morphology and high TNM stage. In addition, these tumors may benefit from treatment with immunotherapy.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • STK11 mutation • PD-L1 negative • ALK mutation • TP53 mutation + KRAS mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS mutation + TP53 mutation
    |
    PD-L1 IHC 22C3 pharmDx